Leveraging AMP® SCZ Findings for Enhanced Psychosis Risk Assessment

Introduction

The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) initiative is a groundbreaking global effort to advance the understanding and treatment of individuals at clinical high risk (CHR) for psychosis. This initiative, the largest of its kind, aims to develop predictive algorithms and novel interventions to address the unmet needs of this vulnerable population. As a practitioner, leveraging the insights from AMP® SCZ can significantly enhance your ability to assess and manage CHR individuals, ultimately improving outcomes and reducing the transition to psychosis.

Understanding the AMP® SCZ Study

AMP® SCZ is a collaborative effort involving multiple international research networks, including ProNET and PRESCIENT, and aims to harmonize data collection and analysis across 43 sites in 13 countries. The study focuses on collecting comprehensive clinical, environmental, and cognitive data, along with multimodal biomarkers such as neuroimaging, electrophysiology, and digital health technology-derived measures. This extensive dataset will facilitate the development of personalized prediction models and targeted interventions.

Key Findings and Implications for Practice

The AMP® SCZ study has highlighted several key findings that can inform clinical practice:

Biomarker Identification: The study has identified multimodal biomarkers that can predict individual clinical trajectories, including the likelihood of progression to psychosis. Practitioners can utilize these biomarkers to stratify CHR individuals and tailor interventions accordingly.
Harmonized Assessment Protocols: By establishing harmonized assessment protocols, AMP® SCZ ensures that data can be pooled across sites, enhancing the generalizability of findings. Practitioners can adopt these protocols to improve the accuracy and consistency of CHR assessments.
Digital Health Technologies: The integration of digital health technologies, such as smartphone-based surveys and passive sensing, provides real-time insights into patients' experiences and behaviors. Practitioners can leverage these tools to monitor CHR individuals more effectively and intervene promptly when necessary.

Encouraging Further Research

While AMP® SCZ provides a robust framework for understanding CHR individuals, there is still much to learn. Practitioners are encouraged to engage in further research to explore the nuances of CHR trajectories and outcomes. By participating in research networks or collaborating with academic institutions, practitioners can contribute to the growing body of knowledge and improve care for CHR individuals.

Conclusion

The AMP® SCZ initiative represents a significant step forward in the early detection and intervention of psychosis. By implementing the study's findings and encouraging further research, practitioners can enhance their skills and improve outcomes for CHR individuals. To read the original research paper, please follow this link: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Citation: Wannan, C. M. J., Nelson, B., Addington, J., Allott, K., Anticevic, A., Arango, C., Baker, J. T., Bearden, C. E., Billah, T., Bouix, S., Broome, M. R., Buccilli, K., Cadenhead, K. S., Calkins, M. E., Cannon, T. D., Cecci, G., Chen, E. Y. H., Cho, K. I. K., Choi, J., Clark, S. R., Coleman, M. J., Conus, P., Corcoran, C. M., Cornblatt, B. A., Diaz-Caneja, C. M., Dwyer, D., Ebdrup, B. H., Ellman, L. M., Fusar-Poli, P., Galindo, L., Gaspar, P. A., Gerber, C., Glenthøj, L. B., Glynn, R., Harms, M. P., Horton, L. E., Kahn, R. S., Kambeitz, J., Kambeitz-Ilankovic, L., Kane, J. M., Kapur, T., Keshavan, M. S., Kim, S.-W., Koutsouleris, N., Kubicki, M., Kwon, J. S., Langbein, K., Lewandowski, K. E., Light, G. A., Mamah, D., Marcy, P. J., Mathalon, D. H., McGorry, P. D., Mittal, V. A., Nordentoft, M., Nunez, A., Pasternak, O., Pearlson, G. D., Perez, J., Perkins, D. O., Powers, A. R. III, Roalf, D. R., Sabb, F. W., Schiffman, J., Shah, J. L., Smesny, S., Spark, J., Stone, W. S., Strauss, G. P., Tamayo, Z., Torous, J., Upthegrove, R., Vangel, M., Verma, S., Wang, J., Rossum, I. W.-v., Wolf, D. H., Wolff, P., Wood, S. J., Yung, A. R., Agurto, C., Alvarez-Jimenez, M., Amminger, P., Armando, M., Asgari-Targhi, A., Cahill, J., Carrión, R. E., Castro, E., Cetin-Karayumak, S., Chakravarty, M. M., Cho, Y. T., Cotter, D., D'Alfonso, S., Ennis, M., Fadnavis, S., Fonteneau, C., Gao, C., Gupta, T., Gur, R. E., Gur, R. C., Hamilton, H. K., Hoftman, G. D., Jacobs, G. R., Jarcho, J., Ji, J. L., Kohler, C. G., Lalousis, P. A., Lavoie, S., Lepage, M., Liebenthal, E., Mervis, J., Murty, V., Nicholas, S. C., Ning, L., Penzel, N., Poldrack, R., Polosecki, P., Pratt, D. N., Rabin, R., Rahimi Eichi, H., Rathi, Y., Reichenberg, A., Reinen, J., Rogers, J., Ruiz-Yu, B., Scott, I., Seitz-Holland, J., Srihari, V. H., Srivastava, A., Thompson, A., Turetsky, B. I., Walsh, B. C., Whitford, T., Wigman, J. T. W., Yao, B., Yuen, H. P., Ahmed, U., Byun, A. (J. S.), Chung, Y., Do, K., Hendricks, L., Huynh, K., Jeffries, C., Lane, E., Langholm, C., Lin, E., Mantua, V., Santorelli, G., Ruparel, K., Zoupou, E., Adasme, T., Addamo, L., Adery, L., Ali, M., Auther, A., Aversa, S., Baek, S.-H., Bates, K., Bathery, A., Bayer, J. M. M., Beedham, R., Bilgrami, Z., Birch, S., Bonoldi, I., Borders, O., Borgatti, R., Brown, L., Bruna, A., Carrington, H., Castillo-Passi, R. I., Chen, J., Cheng, N., Ching, A. E., Clifford, C., Colton, B.-L., Contreras, P., Corral, S., Damiani, S., Done, M., Estradé, A., Etuka, B. A., Formica, M., Furlan, R., Geljic, M., Germano, C., Getachew, R., Goncalves, M., Haidar, A., Hartmann, J., Jo, A., John, O., Kerins, S., Kerr, M., Kesselring, I., Kim, H., Kim, N., Kinney, K., Krcmar, M., Kotler, E., Lafanechere, M., Lee, C., Llerena, J., Markiewicz, C., Matnejl, P., Maturana, A., Mavambu, A., Mayol-Troncoso, R., McDonnell, A., McGowan, A., McLaughlin, D., McIlhenny, R., McQueen, B., Mebrahtu, Y., Mensi, M., Hui, C. L. M., Suen, Y. N., Wong, S. M. Y., Morrell, N., Omar, M., Partridge, A., Phassouliotis, C., Pichiecchio, A., Politi, P., Porter, C., Provenzani, U., Prunier, N., Raj, J., Ray, S., Rayner, V., Reyes, M., Reynolds, K., Rush, S., Salinas, C., Shetty, J., Snowball, C., Tod, S., Turra-Fariña, G., Valle, D., Veale, S., Whitson, S., Wickham, A., Youn, S., Zamorano, F., Zavaglia, E., Zinberg, J., Woods, S. W., & Shenton, M. E. (2024). Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin, 58(6), 1745-1701. https://doi.org/10.1093/schbul/sbae011